# An Exploratory Study of MT-2990 in Patients With AAV

> **NCT06196905** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 5 (actual)

## Conditions studied

- Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)

## Interventions

- **DRUG:** MT-2990

## Key facts

- **NCT ID:** NCT06196905
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-24
- **Primary completion:** 2026-01-14
- **Final completion:** 2026-01-14
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06196905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06196905, "An Exploratory Study of MT-2990 in Patients With AAV". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06196905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*